What is the finding?
Diagnosis, skin type, pigment and scar risk, infection, herpes history, medicines and previous procedures precede any peel.
Chemical Peel · Medical Skin Care · Istanbul
Chemical Peel · Medical Skin Care · Istanbul
Superficial, medium-depth and deep peels differ in tissue effect, recovery and monitoring and are not one routine skin-care method. A named care method, ingredient or infusion is not a diagnosis and does not establish personal suitability.
Online information cannot diagnose, select products or procedures, or promise an outcome. Final decisions require an in-person medical assessment.
Clinical Orientation
Finding · identity · evidence · safety
The sequence prevents a category name from becoming an automatic treatment recommendation.
Diagnosis, skin type, pigment and scar risk, infection, herpes history, medicines and previous procedures precede any peel.
Agent, formulation, concentration, pH, layers or passes, contact time, neutralisation and intended depth are product- and protocol-specific.
Benefits and harms cannot be generalised across peel depths, formulations, diagnoses or skin types.
Urgent review is required for eye exposure, severe pain, blistering, spreading redness, discharge, delayed healing or marked colour change.
What is a Chemical Peel?
Chemoexfoliation · Target layer · Healing
Depending on the protocol, a defined chemical stimulus produces superficial or deeper renewal. Visible flaking alone does not show the actual treatment depth.
What a Chemical Peel can do
What a Chemical Peel cannot do
Superficial, medium-depth and deep peels are not interchangeable intensity levels. Wound, aftercare and complication framework all change with depth.
Medical Suitability
Diagnosis and activity before care
History, examination, current treatment, contraindications and a proportionate alternative are reviewed together.
Diagnosis, skin type, pigment and scar risk, infection, herpes history, medicines and previous procedures precede any peel.
Medicines, allergies, previous procedures or infusions and relevant reactions are considered.
Agent, formulation, concentration, pH, layers or passes, contact time, neutralisation and intended depth are product- and protocol-specific.
Skin care, disease-directed treatment, microneedling, a device-based option, observation or no procedure
Urgent review is required for eye exposure, severe pain, blistering, spreading redness, discharge, delayed healing or marked colour change.
Care Path
Before · during · after
Agent, formulation, concentration, pH, layers or passes, contact time, neutralisation and intended depth are product- and protocol-specific.
Diagnosis, skin type, pigment and scar risk, infection, herpes history, medicines and previous procedures precede any peel.
Agent, formulation, concentration, pH, layers or passes, contact time, neutralisation and intended depth are product- and protocol-specific.
Urgent review is required for eye exposure, severe pain, blistering, spreading redness, discharge, delayed healing or marked colour change.
No personal acid concentration, contact time, prescription medicine or home-treatment recipe is published.
Evidence and Limits
Method-, product- and indication-specific
Benefits and harms cannot be generalised across peel depths, formulations, diagnoses or skin types.
Evidence in one diagnosis or deficiency does not establish a general effect.
Agent, formulation, concentration, pH, layers or passes, contact time, neutralisation and intended depth are product- and protocol-specific.
Symptoms, photographs, laboratory values and patient-reported outcomes are not interchangeable.
Deep peels may require anaesthesia or systemic monitoring and must not be presented as ordinary skin care.
Manufacturer information may identify a product and instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
No automatic peel series
The first peel has a limited aim. Skin response and healing determine whether to repeat, change or stop.
Document the diagnosis, phototype, target area and pigmentation status.
Choose the mildest suitable protocol for the defined aim.
Follow the wound, redness, pigmentation and symptoms separately.
Repeat, change, pause or end the method.
Course and Follow-Up
Expected response · complication · reassessment
Tolerance and the agreed clinical endpoint are reviewed separately before any further intervention.
Record the starting clinical context and intended endpoint.
Observe tolerance and unexpected reactions.
Compare the relevant finding without automatic attribution.
Urgent review is required for eye exposure, severe pain, blistering, spreading redness, discharge, delayed healing or marked colour change.
Risks and Alternatives
Actively prevent chemical burns
Possible complications include chemical burns, infection, herpes reactivation, persistent redness, hyperpigmentation or hypopigmentation and scarring.
Active infection, open skin, marked inflammation or a recent tan may require postponement.
Phototype, a history of melasma or PIH and photoprotection change the risk assessment.
Rubbing, removing crusts, using active ingredients too early or unprotected sun exposure can disrupt healing.
Severe pain, blisters, a weeping wound, fever or rapidly darkening discolouration are warning signs.
Unexpectedly severe or worsening symptoms need timely local examination. Photographs or messages do not replace wound and infection assessment.
Istanbul and Follow-Up
Assessment and review must travel together
Travel does not shorten observation or remove the need for local medical access.
History and existing records prepare discussion without confirming treatment.
Diagnosis, skin type, pigment and scar risk, infection, herpes history, medicines and previous procedures precede any peel.
Agent, formulation, concentration, pH, layers or passes, contact time, neutralisation and intended depth are product- and protocol-specific.
Urgent review is required for eye exposure, severe pain, blistering, spreading redness, discharge, delayed healing or marked colour change.
The Doctor Aslan Approach

Medical position
Dr İsmail Aslan does not plan chemical peels by trend names or the desired amount of peeling. Diagnosis, skin phototype, documented product, controlled endpoint and reliable aftercare must fit together.
A pigmented mark or scar is medically classified before the method is chosen.
Concentration is assessed only together with pH, formulation, time, layers and endpoint.
More peeling does not automatically mean more benefit, but it does create a different healing risk.
Treatment is not planned without suitable photoprotection, wound care and accessible review.
Frequently Asked Questions
Short and clear
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
Not the acid name or percentage alone. Agent, concentration, pH, vehicle, applied quantity, number of layers, contact time, skin preparation, anatomical region and observed endpoint influence penetration. Superficial, medium-depth and deep peels are therefore planned as different medical procedures.
No. Depending on concentration, layers and contact time, high-strength glycolic, salicylic, lactic or trichloroacetic acid can cause an uncontrolled chemical burn. Pain, infection, pigment change and scarring are possible. A professional peel protocol is not for self-application.
Any controlled inflammation may cause post-inflammatory hyperpigmentation; deeper peels can also cause lightening. Phototype, a history of melasma or PIH, tanning, active inflammation and photoprotection affect risk. Darker skin is not an automatic exclusion, but requires appropriate experience and a conservative protocol.
Photographs, aim, medicines, previous peels, herpes, scar and pigment reactions, and sun exposure can be organised online. Diagnosis and peel depth are decided only after in-person examination; skin preparation, the visible healing window, early review, return travel, warning signs and a local medical contact are agreed in advance.
Next Step
Define the question · verify the option · compare alternatives